Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Receivables (2016 - 2025)

Historic Receivables for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $19.7 million.

  • UroGen Pharma's Receivables fell 1359.09% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year decrease of 1359.09%. This contributed to the annual value of $20.3 million for FY2024, which is 3146.41% up from last year.
  • As of Q3 2025, UroGen Pharma's Receivables stood at $19.7 million, which was down 1359.09% from $19.6 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Receivables high stood at $22.8 million for Q3 2024, and its period low was $6.3 million during Q1 2021.
  • For the 5-year period, UroGen Pharma's Receivables averaged around $14.1 million, with its median value being $12.8 million (2023).
  • Per our database at Business Quant, UroGen Pharma's Receivables surged by 226616.92% in 2021 and then plummeted by 1359.09% in 2025.
  • Over the past 5 years, UroGen Pharma's Receivables (Quarter) stood at $11.7 million in 2021, then grew by 8.42% to $12.7 million in 2022, then grew by 21.56% to $15.4 million in 2023, then skyrocketed by 31.46% to $20.3 million in 2024, then dropped by 2.95% to $19.7 million in 2025.
  • Its Receivables stands at $19.7 million for Q3 2025, versus $19.6 million for Q2 2025 and $19.6 million for Q1 2025.